PPK (ASX:PPK) share price wobbles on joint venture news

The company will manufacture anti-viral and anti-bacterial face masks with a new partner…

Shares in PPK Group Limited (ASX: PPK) are up and down in morning trade today. This comes after the boron nitride nanotubes (BNNT) company announced a joint venture to manufacture anti-viral and anti-bacterial face masks.

At the time of writing, the PPK share price is down 0.6% trading at $19.92, after touching a high of $20.6 near the open.

A group of young people clowning around wearing COVID-19 masks

Image source: Getty Images

PPK eyes new revenue stream

In today's statement, PPK advised it has teamed up with Xefco to form a new company called Survivon.

Founded in 2018, Xefco uses advanced manufacturing methods to create textile technologies with additional functional benefits. In particular, the group focuses on antiviral technology.

The newly-formed business will immediately start local production of anti-viral and antibacterial face masks using Xefco's ground-breaking technology. PPK advised it has purchased a mask factory in Brisbane and has orders already in hand. Up to 5 million masks can be produced each month.

The company said the medical-grade face masks would contain an ultra-thin coating of 99.95% pure copper developed by Xefco and Deakin University.

An independent study by the Peter Doherty Institute for Infection and Immunity revealed positive results in May. It showed that the new treated textiles were able to inactivate the virus associated with COVID-19 by 97.79% in 5 minutes, and 99.95% in 15 minutes.

PPK and Xefco will each own 47.6% of Survivon with the remaining balance held by senior manager, Matthew Bailey.

Under the terms of the partnership, PPK will contribute $4.5 million in cash on completion in exchange for its equity, less the transfer of PPK's recently acquired business, Mask Innovation to Survivon for approximately $1.6 million.

The cash will be used as ordinary working capital for the new business.

Management commentary

PPK executive chair Robin Levison commented:

The chance to combine the manufacturing assets of PPK's Mask Innovation business with leading science developed by Xefco in conjunction with Deakin University represents a tremendous commercialisation opportunity with global application.

It is also an incredibly timely one and yields a likelihood of making a very practical and immediate difference in combating one of the great healthcare issues of our time.

About the PPK share price

Over the last 12 months, the PPK share price has accelerated, gaining around 420% since this time last year. Year-to-date, its shares have advanced 240%.

PPK presides a market capitalisation of roughly $1.78 billion, and has 89.29 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »